Product logins

Find logins to all Clarivate products below.


Orforglipron (Foundayo™)

Learn how orforglipron is changing the obesity and T2DM landscape.

Related insights

The FDA approved Foundayo™ (orforglipron) for adults with obesity or overweight with weight-related medical problems The FDA approved Foundayo™ (orforglipron) for adults with obesity or overweight with weight-related medical problems
April 1, 2026
The FDA approved Foundayo™ (orforglipron) for adults with obesity or overweight with weight-related medical problems
This makes Foundayo the first FDA-approved non-peptide oral GLP-1 RA for obesity/overweight and Eli Lilly and Co’s second obesity drug approved by the FDA. Approval was based on positive data from the ATTAIN clinical trial program. The company says it will make Foundayo available first via LillyDirect®, with shipping expected to begin April 6, after which it will become available via U.S. retail pharmacies and telehealth providers.
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
December 18, 2025
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
Eli Lilly and Co reported positive topline results at one year from the ATTAIN-MAINTAIN trial involving participants from SURMOUNT-5, comparing orforglipron vs placebo for weight maintenance. Orforglipron provided superior percent maintenance of body weight reduction.
chevron_left
chevron_right

What is orforglipron (Foundayo) and what sets it apart

Orforglipron is the first non-peptide oral glucagon-like peptide-1 (GLP-1) receptor agonist (RA) approved by the FDA. The approval was granted for obesity, with the brand name as Foundayo. The type 2 diabetes mellitus (T2DM) approval is awaited.

Novel therapies like this aim to address limitations such as suboptimal real-world adherence by improving the administration route via its mechanism of action. It could help shift the treatment paradigm to better align with patients’ needs.

About orforglipron

  • Company: Eli Lilly and Co
  • Type: Small-molecule GLP-1 RA
  • Usage: Once-daily oral administration without any food or water restrictions to manage obesity (Foundayo) and T2DM
    Also being evaluated for obstructive sleep apnea (OSA) and hypertension in individuals with obesity
  • When will orforglipron be available?
    Actual launch 2026: United States (obesity: Foundayo)
    Expected launch 2026: United States (T2DM)
    Expected launch 2027: European Union (obesity and T2DM), Japan (obesity and T2DM), United Kingdom (obesity and T2DM)

Orforglipron sales and success forecasts

$11.1bn
expected sales for obesity in the G7 markets in 2031*
90%
probability of success for obesity in the United States
$5.2bn
expected sales for T2DM in the G7 markets in 2031*
90%
probability of success for T2DM in the United States

*Because the obesity and T2DM populations overlap, reported sales are not exclusive to each market.

Pills are always easier than injections. Moreover, orforglipron is better as it is not a peptide. Such molecules get absorbed much more easily.

Endocrinologist United States

Drugs in the 2026 list

Related insights

What GLP-1 drugs mean for medtech What GLP-1 drugs mean for medtech
Blog July 2, 2024
What GLP-1 drugs mean for medtech

Are the powerful weight loss and diabetes treatments a lose-lose for medical technology companies? Not necessarily.

The impact of GLP-1RAs on bariatric surgery The impact of GLP-1RAs on bariatric surgery
Webinar
The impact of GLP-1RAs on bariatric surgery

Glucagon-like peptide-1 (GLP-1) receptor agonists have recently witnessed a meteoric rise in popularity for obesity and weight loss. Studies have shown that GLP-1 receptor agonists can be effective for people with obesity, promoting sustained weight management and potentially reducing the risk of weight-related comorbidities. The initial surge in the adoption of these drugs is anticipated...

chevron_left
chevron_right